Quinn Opportunity Partners LLC Has $9.32 Million Stock Position in Illumina, Inc. $ILMN

Quinn Opportunity Partners LLC grew its position in Illumina, Inc. (NASDAQ:ILMN) by 96.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 97,687 shares of the life sciences company’s stock after purchasing an additional 47,885 shares during the period. Quinn Opportunity Partners LLC owned about 0.06% of Illumina worth $9,320,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. Rise Advisors LLC grew its stake in shares of Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after buying an additional 224 shares in the last quarter. Parkside Financial Bank & Trust lifted its stake in Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 115 shares during the last quarter. Cullen Frost Bankers Inc. bought a new stake in Illumina in the second quarter worth approximately $41,000. NewSquare Capital LLC grew its position in Illumina by 604.9% in the second quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after acquiring an additional 369 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Illumina by 2,936.8% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock valued at $46,000 after purchasing an additional 558 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Price Performance

NASDAQ ILMN opened at $122.60 on Wednesday. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $153.06. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The stock has a market capitalization of $18.73 billion, a PE ratio of 15.52, a P/E/G ratio of 2.34 and a beta of 1.42. The stock has a 50-day simple moving average of $101.44 and a 200 day simple moving average of $95.20.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the firm posted $1.14 EPS. The company’s revenue was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ILMN shares. Canaccord Genuity Group lifted their price objective on shares of Illumina from $105.00 to $112.00 and gave the company a “hold” rating in a research note on Friday, October 31st. Robert W. Baird set a $109.00 price target on Illumina in a research report on Friday, October 31st. Evercore ISI upped their price target on Illumina from $132.00 to $142.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. Daiwa Capital Markets downgraded Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price objective on the stock. in a research note on Tuesday, August 12th. Finally, Daiwa America cut Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 12th. Five investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, Illumina has a consensus rating of “Hold” and an average target price of $115.00.

Insider Transactions at Illumina

In related news, Director Scott Gottlieb bought 500 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The shares were acquired at an average price of $122.13 per share, with a total value of $61,065.00. Following the completion of the transaction, the director owned 12,523 shares of the company’s stock, valued at $1,529,433.99. The trade was a 4.16% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.60% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.